Day One Biopharmaceuticals (NASDAQ:DAWN) Announces Earnings Results, Misses Expectations By $0.04 EPS

Day One Biopharmaceuticals (NASDAQ:DAWN) issued its quarterly earnings results on Tuesday. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.04), FiscalAI reports. Day One Biopharmaceuticals had a negative return on equity of 32.05% and a negative net margin of 113.53%.The business had revenue of $53.72 million during the quarter, compared to analyst estimates of $49.81 million.

Here are the key takeaways from Day One Biopharmaceuticals’ conference call:

• OJEMDA commercial traction: 2025 net product revenue was $155.4M (up 172% YoY) with Q4 revenue of $52.8M and >4,600 prescriptions; management reiterated 2026 OJEMDA guidance of $225M–$250M.
• Three‑year FIREFLY‑1 data strengthen clinical case: company reports a 53% objective response rate, median response duration ~19.4 months, no new safety signals, and a median time‑to‑next‑treatment (TTNT) of 42.6 months versus a 16.6‑month PFS, which management says supports durable clinical benefit.
• Pipeline and BD progress: acquisition of Mersana closed in January to add Emi‑Le (early activity in adenoid cystic carcinoma) with an updated dataset planned for mid‑2026 and potential accelerated development, plus DAY301 early signals expected H2 2026.
• Concentration and timing risks remain: Day One is heavily dependent on OJEMDA as its primary revenue driver and future performance hinges on persistence, new patient starts, payer dynamics, and successful enrollment/readout of FIREFLY‑2 (top‑line mid‑2027); statements are forward‑looking and company‑presented.

Day One Biopharmaceuticals Price Performance

DAWN stock traded down $1.00 during mid-day trading on Wednesday, reaching $11.02. 2,033,873 shares of the company’s stock were exchanged, compared to its average volume of 2,447,963. Day One Biopharmaceuticals has a 12-month low of $5.64 and a 12-month high of $13.20. The stock’s 50 day moving average is $10.63 and its 200 day moving average is $8.74. The company has a market cap of $1.13 billion, a price-to-earnings ratio of -7.26 and a beta of -1.26.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on DAWN shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a research note on Monday, December 29th. TD Cowen assumed coverage on Day One Biopharmaceuticals in a research note on Tuesday, January 13th. They set a “buy” rating and a $34.00 price objective for the company. Piper Sandler upped their target price on Day One Biopharmaceuticals from $25.00 to $26.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 5th. Needham & Company LLC dropped their target price on Day One Biopharmaceuticals from $18.00 to $17.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, HC Wainwright decreased their price target on Day One Biopharmaceuticals from $25.00 to $22.00 and set a “buy” rating for the company in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $26.14.

Day One Biopharmaceuticals News Roundup

Here are the key news stories impacting Day One Biopharmaceuticals this week:

• Positive Sentiment: Record revenue and reaffirmed 2026 outlook — Day One reported Q4 product revenue of ~$52.8M and full‑year 2025 net product revenue of $155.4M, beating consensus. Management reaffirmed 2026 U.S. net product revenue guidance of $225–$250M, which supports growth expectations. Press Release
• Positive Sentiment: Pipeline expansion via acquisition — The company completed the January acquisition of Mersana, adding Emi‑Le (Phase 1 for ACC) and expanding oncology pipeline optionality, a longer‑term positive for valuation if assets advance. Press Release
• Positive Sentiment: Wedbush raises price target — Wedbush bumped its PT from $29 to $30 and maintained an “outperform” call, implying meaningful upside versus current levels and giving bullish third‑party validation. Benzinga TickerReport
• Neutral Sentiment: Earnings materials and call transcripts available — Full Q4 slide deck and earnings‑call transcripts were posted (useful for digging into unit trends, OJEMDA uptake, and margin drivers). These provide detail but are not immediately price‑moving by themselves. Slide Deck Presentation
• Negative Sentiment: EPS miss and margins remain a concern — Reported EPS of ($0.21) missed the ($0.17) consensus and the company still shows negative net margin and ROE, fueling near‑term disappointment and selling pressure despite the revenue beat. MarketBeat
• Negative Sentiment: Mixed analyst reactions — While some firms raised targets, Needham cut its PT to $17 and HC Wainwright trimmed to $22 (both kept “buy”), reflecting differing views on near‑term profitability and risk; the cuts add downward pressure even as other shops remain constructive. Benzinga

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Lauren Merendino sold 5,814 shares of the company’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total transaction of $67,442.40. Following the completion of the transaction, the insider directly owned 60,157 shares in the company, valued at approximately $697,821.20. This represents a 8.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Michael Vasconcelles sold 2,728 shares of Day One Biopharmaceuticals stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total transaction of $31,644.80. Following the completion of the sale, the insider owned 4,397 shares in the company, valued at approximately $51,005.20. This trade represents a 38.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 36,461 shares of company stock worth $422,948. 6.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of DAWN. Royal Bank of Canada boosted its holdings in Day One Biopharmaceuticals by 40.4% in the 1st quarter. Royal Bank of Canada now owns 185,733 shares of the company’s stock worth $1,474,000 after buying an additional 53,459 shares during the last quarter. AQR Capital Management LLC boosted its stake in shares of Day One Biopharmaceuticals by 601.4% in the first quarter. AQR Capital Management LLC now owns 618,627 shares of the company’s stock worth $4,906,000 after acquiring an additional 530,429 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Day One Biopharmaceuticals by 6.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,992 shares of the company’s stock worth $302,000 after purchasing an additional 2,149 shares in the last quarter. Millennium Management LLC increased its position in shares of Day One Biopharmaceuticals by 587.2% during the first quarter. Millennium Management LLC now owns 1,320,095 shares of the company’s stock worth $10,468,000 after purchasing an additional 1,127,995 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in Day One Biopharmaceuticals by 232.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,569,918 shares of the company’s stock valued at $12,449,000 after purchasing an additional 1,097,679 shares during the last quarter. 87.95% of the stock is owned by hedge funds and other institutional investors.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.